In some difficult to treat, or particularly aggressive cancers, synergistic effects were found between GL-ONC1 and traditional chemotherapy drugs. For example, the graph below shows additive beneficial effects of GL-ONC1 in female nude mice when paired with cisplatin in a combination treatment for ovarian cancer.
The red arrow indicates the time of GL-ONC1 injection and the green arrows indicate the times when chemotherapy was administered. In the ovarian cancer study, the combination of GL-ONC1 treatment with chemotherapy resulted in significant enhancement of the antitumor therapy as compared to either treatment alone. This suggests the potential of combination therapy for difficult to treat cancers, where the chemotherapy may sensitize the tumors for even better response to oncolytic virotherapy.
Similar preclinical results involving combination therapy have been found for pancreatic cancer, as well as for mesothelioma. Such synergistic anti-tumor effects could potentially be delivered with a reduced cumulative toxicity for cancer patients.